XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(FY)Sep 30, 2024 | (FY)Sep 30, 2023 | (FY)Sep 30, 2022 | (FY)Sep 30, 2021 | |
---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||
Cash flow from continuing operating activities | -38.28%-10.07M | -49.69%-7.28M | -116.95%-4.86M | -2.24M |
Net income from continuing operations | -5.28%-11.11M | -71.11%-10.55M | -7.25%-6.17M | ---5.75M |
Operating gains losses | ---- | -490.00%-78K | 101.73%20K | ---1.16M |
Depreciation and amortization | -23.25%307K | -10.11%400K | -29.48%445K | --631K |
Other non cash items | ---29K | ---- | ---- | ---- |
Change In working capital | -117.30%-77K | -44.31%445K | -77.01%799K | --3.48M |
-Change in receivables | -210.84%-184K | -73.44%166K | 48.46%625K | --421K |
-Change in inventory | -1,031.19%-2.29M | 58.18%-202K | -129.96%-483K | --1.61M |
-Change in prepaid assets | -199.02%-4.67M | 209.46%4.71M | 55.76%-4.3M | ---9.73M |
-Change in payables and accrued expense | 2,410.50%8.8M | -112.15%-381K | 36.75%3.14M | --2.29M |
-Change in other current assets | ---- | ---- | ---- | --12K |
-Change in other current liabilities | -103.09%-197K | -234.48%-97K | 97.40%-29K | ---1.12M |
-Change in other working capital | 58.72%-1.55M | -302.48%-3.75M | -81.44%1.85M | --9.98M |
Cash from discontinued investing activities | ||||
Operating cash flow | -38.28%-10.07M | -49.69%-7.28M | -116.95%-4.86M | ---2.24M |
Investing cash flow | ||||
Cash flow from continuing investing activities | -178.83%-108K | -92.50%137K | 60.97%1.83M | 1.14M |
Net PPE purchase and sale | -3,150.00%-61K | 100.95%2K | 22.99%-211K | ---274K |
Net other investing changes | -134.81%-47K | -93.38%135K | 44.64%2.04M | --1.41M |
Cash from discontinued investing activities | ||||
Investing cash flow | -178.83%-108K | -92.50%137K | 60.97%1.83M | --1.14M |
Financing cash flow | ||||
Cash flow from continuing financing activities | 44.50%10.48M | 57.86%7.25M | 218.89%4.59M | 1.44M |
Net issuance payments of debt | 633.12%2.53M | 40.08%-474K | -155.55%-791K | --1.42M |
Net common stock issuance | 2.07%9.03M | 464.16%8.85M | 9,700.00%1.57M | --16K |
Net preferred stock issuance | --0 | --0 | --3.82M | --0 |
Net other financing activities | 3.74%-1.08M | ---1.12M | ---- | ---- |
Cash from discontinued financing activities | ||||
Financing cash flow | 44.50%10.48M | 57.86%7.25M | 218.89%4.59M | --1.44M |
Net cash flow | ||||
Beginning cash position | 2.37%2.12M | 176.50%2.07M | 92.54%749K | --389K |
Current changes in cash | 184.76%299K | -93.25%105K | 366.97%1.56M | --333K |
Effect of exchange rate changes | 196.43%54K | 75.97%-56K | -962.96%-233K | --27K |
End cash Position | 16.65%2.47M | 2.37%2.12M | 176.50%2.07M | --749K |
Free cash flow | -39.12%-10.13M | -43.47%-7.28M | -101.71%-5.08M | ---2.52M |
Currency Unit | USD | USD | USD | USD |
Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- |